Johnson & Johnson (JNJ)

118.19
0.92 0.78
NYSE : Health Care
Prev Close 117.27
Open 117.79
Day Low/High 117.39 / 118.62
52 Wk Low/High 91.76 / 126.07
Volume 2.25M
Avg Volume 6.23M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 326.64B
EPS 5.60
P/E Ratio 21.75
Div & Yield 3.20 (2.70%)

Latest News

Heartening News for J&J: Americans Feel 'Great' About the Economy

Heartening News for J&J: Americans Feel 'Great' About the Economy

As consumer confidence and health care spending soar, Johnson & Johnson is becoming one of the best total return packages available.

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

Johnson & Johnson Is Setting Up for a Rally

Johnson & Johnson Is Setting Up for a Rally

Johnson & Johnson's pullback my have finally reached an end. Here's how to trade the stock now.

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Focus on finding stocks of high-quality companies at good prices, Cramer advises.

EpiPen Controversy: Mylan's Tough Week Just Keeps Getting Grimmer

EpiPen Controversy: Mylan's Tough Week Just Keeps Getting Grimmer

Brace for extreme turbulence as Mylan's chief executive testifies before Congress and faces further public condemnation.

Johnson & Johnson Advances Commitment To Improve Global Health And Well-Being

Johnson & Johnson Advances Commitment To Improve Global Health And Well-Being

A New Commitment to 2030 Sustainable Development Goals and Ongoing Support for Refugees

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.

Johnson & Johnson (JNJ) Stock Lower, Buys Abbott Laboratories' Medical Optics Unit for $4.3 Billion

Johnson & Johnson (JNJ) Stock Lower, Buys Abbott Laboratories' Medical Optics Unit for $4.3 Billion

Johnson & Johnson (JNJ) is buying Abbott Laboratories (ABT) medical optics division, which deals with vision care services such as laser vision correction, for $4.3 billion.

Johnson & Johnson Announces Agreement To Acquire Abbott Medical Optics

Johnson & Johnson Announces Agreement To Acquire Abbott Medical Optics

Acquisition to Strengthen Global Leadership in Eye Health Adding Cataract and Refractive Eye Surgery to Vision Care Portfolio

Johnson & Johnson (JNJ) Stock Lower, Purchases 100 Megawatts of Texas Wind Power

Johnson & Johnson (JNJ) Stock Lower, Purchases 100 Megawatts of Texas Wind Power

Johnson & Johnson (JNJ) agreed to buy 100 megawatts from a wind-power development in the Texas Panhandle, a move that furthers the company's existing $339 million invested in clean-energy projects.

Cramer: This Is a Market of Stocks, not a Market of Markets

Cramer: This Is a Market of Stocks, not a Market of Markets

Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.

Perrenial Target and Acquirer NuVasive Names New President and COO

Perrenial Target and Acquirer NuVasive Names New President and COO

The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.

Big Pharma Spends Millions to Keep Prices High for California Agencies

Big Pharma Spends Millions to Keep Prices High for California Agencies

Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.

Johnson & Johnson Announces World Health Organization Will Review Ebola Vaccine Regimen For Emergency Use Assessment And Listing (EUAL)

Johnson & Johnson Announces World Health Organization Will Review Ebola Vaccine Regimen For Emergency Use Assessment And Listing (EUAL)

Preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

When the market decides only one thing is working, that makes things treacherous for everyone else,

Why Boston Scientific Keeps Rising

Why Boston Scientific Keeps Rising

In the last year, shares of Boston Scientific are up almost 50%. Boston Scientific is putting the problems of the past behind it and has a bright future.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Top 10 Dividend Stocks to Buy in September

Top 10 Dividend Stocks to Buy in September

Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.

Here's Why J&J Is the Most Consistent Dividend Stock in the World

Here's Why J&J Is the Most Consistent Dividend Stock in the World

Johnson & Johnson, the most consistent dividend stock in the world with 54 consecutive increases, has also had 32 straight adjusted earnings-per-share increases.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.